Advance Clinical Trials and Research

About Conference

We are pleased to announce the "6th European Conference on Advance Clinical Trials and Research," which will be held on October 24-25, 2024 in Paris, France.

Scientific meetings and conferences play an important role in the scientific process, serving as one of the primary venues for Academicians, Scientists, Practitioners, Students, Scholars, Researchers, and Family physicians, health educators, and social workers, as well as Business professionals, to present and receive feedback on research prior to publication, forge collaborations, and network and share research ideas.

Clinical Trials Congress-2024 is a specially designed two-day event featuring high-quality presentations, keynote addresses, oral presentations and plenary sessions, intense scientific topics, panel discussions, workshops, special sessions, student poster presentations, round table discussions, and exhibition from the world's brightest minds in medical, science, and technology.

Sessions and Tracks

Track 1: Pharmaceutical Technology

Pharmaceutical Technology is the integration of risky scientific aspects in the development and production of new drugs, treatment of medicines, and medicinal devices. Pharmaceutical expertise is the application of scientific knowledge or technology to the fields of pharmacy, pharmacology, and the pharmaceutical industry. It includes methods, techniques, and instrumentation used in the production, preparation, compounding, dispensing, packaging, and storage of drugs, as well as other arrangements used in diagnostic and formative procedures and patient treatment.

Track 2: Clinical Trials

Clinical trials are human research studies that seek to assess the effectiveness of a medical, surgical, or behavioural intervention. They are the main way for researchers to determine whether a new treatment, such as a new drug, diet, or medical device, is safe and effective in humans. A clinical trial is frequently used to determine whether a new treatment is more effective than the standard treatment and/or has fewer harmful side effects. Other clinical trials seek ways to detect a disease early, even before symptoms appear. Others look for ways to avoid a health problem. A clinical trial may also look into ways to improve the lives of people who have a potentially fatal disease or a chronic health problem.

• Drug’s Safety and Efficacy
• Pre Clinical Research
• Clinical Study Designs

Track 3: Clinical Pharmacology and Receptor Therapy

Clinical pharmacology has been practised for hundreds of years through observational studies of the effects of herbal medicines and early medications on people. For a long time, scientific breakthroughs have allowed researchers to revisit the study of physiological and biological consequences. The development of receptor theory for drug effects in clinical pharmacology medicine, which has expanded into a multidisciplinary discipline, has been found to influence drug interaction, therapeutic efficacy, and safety.

The study of pharmacokinetics, which examines drug absorption, distribution, metabolism, and elimination, is included in the field of drug interactions and pharmacology compatibilities. Pharmacodynamics is the term used to describe the pharmacological effect of a medicine on the body. Because drug application, microbial abolition, and resistance are all linked, pharmacokinetic and pharmacodynamic factors are crucial.

• Translational Pharmacology
• Clinical application of systemic pharmacology models
• Pharmacological Testing
• Pharmacotherapeutics
• Receptor theory for drug effects

Track 4: Drug Delivery through Blood-Brain Barrier (BBB)

An unusually strong blood-mind barrier protects and isolates the brain from everyday life. Enzymatic movement, tight intersections, partly impermeable endothelial cells, and dynamic efflux transport frameworks all show this. As a result, the blood-cerebrum border is made to allow for the oppressive transit of atoms necessary for mental function. This creates a significant disagreement on the treatment of focal infections of the sensory system, allowing therapeutic doses of the drug to enter the brain. Some tiny lipophilic drugs diffuse across the blood-brain barrier effectively enough to be effective. However, many potentially useful drugs are prohibited.

• blood-mind obstruction
• enzymatic movement

Track 5: Drug Discovery and Development

Medication disclosure is a flexible cycle by which new therapeutics are extended. From beginning objective distinguishing proof to late-arrange clinical preliminaries, a wide scope of logical staff are needed from across the biosciences and then some. Scholars, protein researchers, therapeutic physicists, pharmacologists, toxicologists and computational researchers all play key parts to play. This cycle is fundamental as it is the means by which new medications, every now and again with novel methods of activity, become available to patients.

Trcak 6: Pharmaceutical Formulation Technologies

Drug information is a combination of chemically active and passive fixings. Injectable measuring details typically contain certain inert fixes, such as buffering specialists, water, co-solvents, and pH-changing specialists. They are therefore easy to acquire detailed information for a component of the semisolid plans used for efficient organisation. Different definition factors and interaction factors make up a drug strategy. The quantitative model-based definition of a medicine includes initial numerical relations that are encased by detailing factors and crisis reactions, and it broadens the plan cases.

• co-solvents
• buffering specialists

Track 7: Pharmaceutical Drug Discovery and Nanotechnology

Nanotechnology has currently at home with produce prescription. engineering contains the use of materials with basic length scales within the nanometres estimation that exhibit altogether modified properties associated with micrometer organized materials. Such materials will incorporate particles, strands, grain sizes, so forth. This session featured the movements engineering is creating in prescription in such fields as illness aversion, analysis, and treatment together with (however not restricted to) tranquilize revelation, tissue planning, inserts, sensors, sickness treatment, a nonetheless not affected to medicate conveyance, tissue building, transplants, sensors, malignant growth treatment, and toxic.

• Drug Resistances
• Nanomaterials

Track 8 :Drug Designing

Drug design is a capable method of discovering medications based on biological targets. It's also known as a rational drug graph or a rational style. The drug is almost always a natural little molecule that stimulates or inhibits the function of a biomolecule, such as a supermolecule, resulting in a therapeutic benefit to the patient. In its most basic form, a drug graph is dependent on data from the three-dimensional structure of building block targets. The drug is a natural molecule that, once targeted, will either inhibit or remove the feature of a biomolecule that results in therapeutic benefit. A drug sketch is a unique method of medication determined by organic target.

• Structure based drug design
• Ligand based drug design

Track 9: Pharmacovigilance

Medicines and vaccines have revolutionised disease prevention and treatment. Medicinal products, in addition to their benefits, may have side effects, some of which may be undesirable and/or unexpected. Pharmacovigilance is the science and activities concerned with the detection, assessment, comprehension, and prevention of adverse effects or other medicine/vaccine-related issues.

Track 10: Factors that affect the quality and efficiency of clinical trials

Drug development has been extremely drawn out, expensive, and ineffectual over the past few decades, especially for phase III or confirmatory trials, which are carried out to demonstrate the favourable safety-efficacy balance of medications for clinical application. Phase III trial failure can have severe repercussions; the financial loss resulting from the stoppage of development may have a negative effect on upcoming preclinical and clinical research investments. To ensure that new, reasonably priced medications are consistently available on the market, it is crucial to optimise the success rates and effectiveness of these trials. Adopting novel ideas in clinical trials and using effective techniques accepted by the FDA and EMA are crucial to success. The effectiveness and quality of clinical trials are influenced by a variety of factors.

Track 11: Side Effects

Side effects are unwanted or unexpected symptoms or sensations that develop after taking a medication. Minor side effects like a headache or dry mouth can occur. Additionally, they can be fatal, such as major bleeding or permanent liver or kidney damage. Drug side effects may potentially impair your ability to drive.

Trcak 12: Issues in Multicenter Clinical Trials

Clinical trials at the late stages are expensive and ineffective. Simple assumptions result in a trial that is underpowered, not properly accounting for variation. The drug supply chain can be quite wasteful. Independent design choices are made for interrelated elements.

• Interacting Design Factors
• Recruitment of patients
• How many facilities are there, how long is the wait, etc.
• Randomization
• Statistical simulation
• The number of patients, ideal analysis model, etc.
•  Patient abandonment
•  Drug supply

Trcak 13: Data Resources in the Health Sciences

The majority of health and medical research relies heavily on clinical data. Either as part of a formal clinical trial programme or as part of ongoing patient treatment, clinical data is gathered. Six main categories of clinical data exist

• Digital health records
• Financial information
• Data on claims
• Disease and patient registries
• Medical studies
• Data from clinical trials

Trcak 14: Biomarkers

Although there are numerous crucial applications for biomarkers in clinical practise and product testing, most of them have not been proven to accurately predict clinical outcomes. Several of these case studies demonstrate how promising phase 2 biomarker data does not always transfer into successful product performance. Phase 2 testing of medications for disorders including AD (semagacestat), cardiac disease (aliskiren, darapladib, torcetrapib), Staph infection (V710 vaccine), and herpes infection (herpes simplex) revealed positive biomarker results (HSV-2 vaccine). In phase 3 trials, these investigational goods were not shown to be productive.

Track 15: Biomarker Discovery and Drug Development

The process of creating a new medicine can be difficult and require a number of intricate steps. Every stage of the drug development process, including the initial identification of potential drugs, translational research, clinical development, and reverse translational studies, requires the use of well-validated biomarkers in order to avoid costly errors.

Through all of these phases, effective biomarker discovery and validation are made possible by NanoString's systems. No matter what kind of spatial analysis your research calls for—bulk, single-cell, or sub-cellular—our cutting-edge technology can hasten your scientific findings in the field of drug development.

Track 16: Clinical Trials & Pharmacovigilance

Clinical trials are a phase-by-phase process for determining a chemical or biological compound's safety and efficacy. An investigator keeps a careful eye on the pharmaceutical firm that is involved in the research and development of a medicinal product. Independent Assess Boards, Ethics Committees, and drug safety consulting businesses independently review the procedure. This procedure includes Pharmacovigilance which ensures that patients receive safe and effective medications. Pharmacovigilance is the study of detecting, preventing, or minimising harmful effects produced by a medicine.

• Drug’s Safety and Efficacy
• Pre Clinical Research
• Clinical Study Designs

Track 17: Patient Centric Clinical Trials

Patients require an ethical and long-term relationship, which reflects in how medications are developed and not considering patients as disposable commodities, but as an integral and valuable collaborator in the process. Second, patients expect to be respected for who they are and what they have to say. Many of the barriers to accessing reliable medical information have been decreased or eliminated. Physicians and pharmaceutical corporations no longer have exclusive access to knowledge about diseases and medical problems, allowing even patients with the highest regard for their doctors to complement physician-provided information with their own layman's research.

• Clinical Development
• Research and Discovery
• Open Communication Channels

Track  18:  Adaptive Trial Model

An adaptive clinical trial is a clinical trial that examines a medical equipment or treatment by evaluating potentially other measures, such as side effects, on a predetermined schedule and then modifying the trial protocol parameters in response to those observations. The adaption process, in general, continues throughout the trial as specified in the protocol. There are modifications to the dosage, sample size, medicine being tested, and patient selection criteria. As additional information becomes available, trials become an ongoing process that includes new medicines and patient groups. Before the trial begins, the trial protocol is established, and the protocol describes the adaption timeline and methods..

• Estimating treatment effects
• Trial planning
• Maintaining trial conduct and integrity

Trcak  19: Post-Clinical Trial closed communities

Clinical trials are essential for developing newer and better treatments to benefit humanity. It is the most costly and time-consuming step in the development of a new medicine. Currently, the scientific period and research are making significant progress in all fields, and more and better pharmaceuticals are being developed to address disorders that are tough to treat. Clinical trials are supervised by a set of well-defined rules that must be followed, but they are nonetheless viewed as a humanitarian concern at times. Because patients are at the centre of every clinical research project, all clinical research guidelines are geared on safeguarding the rights, following the rules, and ensuring the safety and well-being of study participants.

• Post trial access
• Drug Marketing
• Clinical Trial Diversity

Trac 20 : Clinical Data Strategy and Analytics

Only large firms can afford a complete data strategy, which is necessary for building a regulated data flow and prioritising strategy. Data strategy aids in the organization's emphasis on the most pressing issues, ensuring that end users receive value fast. The issues and data confusion that arise with having several CROs and data source suppliers were shared by eCS clients as a software technology enabled data services provider. A structured data strategy can assist firms overcome these obstacles by allowing them to acquire control of the data in which they have invested so much.

• Clinical Data Management
• Automation
• Analytics

Track 21: Clinical Trial Auditing

Independent and methodological review of clinical research activities and documents to determine whether activities related to the establishment and monitoring of this clinical research were carried out, and if data was collected, analysed, and reported in accordance with the protocol and standardised operating procedures. System audits should be small enough to be manageable given the resources available (can be managed). Audits must be planned and carried out in a way that produces acceptable results. Most crucial, do not decrease your audit programme; instead, provide time for unscheduled audits.

• Pre-study Qualification Visit
• Monitoring of Clinical Trials
• Auditing of Clinical Trials

Track 22: Implementing Risk Based Monitoring

Clinical trial costs and complexity have risen considerably in recent years. The conventional on-site evaluation of trial data accounts for one-third of the study's expense. This method, which relies primarily on comprehensive source data verification, has shown to be both resource-intensive and restricted in its capacity to detect and avoid problems. It is widely acknowledged that the procedure for clinical trial monitoring needs to alter in order to ensure the well-being of trial participants and retain the integrity of final results.

• Data Integrity
• Detection of Critical Data and Processes
• Risk Assessment

Trcak 23: Oncology Clinical Research

Oncology research has a wide range of applications, and clinical trial and study designs are becoming increasingly sophisticated. According to current reports, the success rate of investigational compounds approved for clinical usage in cancer is the lowest of all disorders, with only 6.7 percent of oncology treatments examined in Phase I trials receiving approval. Clinical trials in oncology have a wide range of outcomes. Understanding the distinctions can help enhance both the impact of cancer research on clinical practise and the efficient use of limited resources.

• Cancer subtypes
• Creation of oncology study data
• Systematic evaluation

Track 24 : Imaging Research

Medical imaging is the technique of creating images of bodily components for medical purposes such as detecting or studying diseases. Every week, millions of imaging procedures are performed all over the world. Medical imaging is rapidly evolving as image processing techniques such as picture recognition, analysis, and enhancement advance. Image processing improves the percentage of tissues identified as well as the number of tissues detected. The use of image analysis techniques in this subject describes how to solve image interpretation problems with various image processing algorithms as k-means, ROI-based segmentation, and watershed techniques.

• Digital Image Processing
• Medical Imaging Systems
• Image Processing Techniques

Track 25: Post Marketing Surveillance

The science of pharmacovigilance includes post-market surveillance, which involves monitoring the safety of a pharmaceutical medicine or medical device after it has been released on the market. Since drugs and medical devices are accepted and approved based on clinical trials, which involve relatively small numbers of people who do not normally have other medical conditions that exist in the general population, post-marketing surveillance can refine or confirm the safety of a drug or device after it has been used in the general population by large numbers of people with a variety of medical conditions

• Pharmacovigilance
• Marketing Authorization
• Strategy and Drug Research

Market Analysis

The global clinical trials market is experiencing significant growth, driven by various factors across different segments and regions. As of 2023, the market revenue was valued at approximately $48.2 billion, with projections suggesting it will reach $73.2 billion by 2028, marking a compound annual growth rate (CAGR) of 8.7%. This growth is largely attributed to the increasing number of drugs in the pipeline and rising investments in pharmaceutical research and development (R&D), with a favorable outlook for biologics and biosimilars offering additional market opportunities.

North America has been a dominant player in the clinical trials market, accounting for a substantial share, attributed to increased R&D spending by pharmaceutical companies??. Europe also holds a significant market share, while the Asia Pacific region is expected to experience the fastest growth during the forecast period, driven by the rising prevalence of infectious and chronic diseases.

Key segments within the clinical trials market include different phases of clinical trials (Phase I-IV), with Phase II and III trials being particularly critical due to their complexity and cost. The market caters to a wide array of therapeutic areas, including oncology, infectious diseases, neurology, metabolic disorders, and cardiology, among others.

The industry has seen strategic partnerships between pharmaceutical companies and Contract Research Organizations (CROs), as well as rapid adoption of advanced technology, playing pivotal roles in market growth. Prominent players in the market include IQVIA, Laboratory Corporation of America Holdings, and Pfizer, Inc., which have focused on expanding their product portfolios and investing in R&D to improve drug development.

Recent developments include multiyear agreements to enhance clinical trial analysis and operation through machine learning and the establishment of new clinical trial supplies and logistics facilities to expedite trial progress.

Overall, the clinical trials market is characterized by its competitive landscape, with ongoing innovations and strategic collaborations shaping its future growth trajectory.